Skip to content

Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice

A Multi-Center Phase III Study to Evaluate MALG, a Novel Malathion 0.05%Formulation, for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00244439
Enrollment
360
Registered
2005-10-26
Start date
2005-12-31
Completion date
2006-12-31
Last updated
2013-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lice Infestations

Keywords

Head Lice, Pediculosis capitis

Brief summary

Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.

Interventions

DRUGMALG

30 minute application

DRUGOvide (malathion) lotion 0.05%

8-12 hour application

10 minute application

Sponsors

Sun Pharmaceutical Industries, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Confirmed active head lice infestation * Patient, parent or guardian must be able to apply the treatment * Entire household must be screened * All infested persons must agree to participate

Exclusion criteria

* Allergy to pediculicides, hair care products or chrysanthemums * Scalp conditions other than head lice * Previous head lice treatment within the past 4 weeks * Female patients who are pregnant or nursing

Design outcomes

Primary

MeasureTime frame
Cure of Head Lice4 weeks

Secondary

MeasureTime frame
Safety of treatments4 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026